Read by QxMD icon Read


Tim Child, Saoirse A Leonard, Jennifer S Evans, Amir Lass
Vaginal progesterone via capsule, gel or tablet is the most common route for luteal phase support (LPS) in Europe. Although there is a wealth of data comparing products used at other stages of assisted reproductive technology cycles, there is a lack of systematically identified evidence comparing the wide range of vaginal progesterone products. This systematic review queried the MEDLINE, Embase and Cochrane Library databases on 30 June 2016 to identify head-to-head randomized controlled trials (RCTs) comparing the efficacy or safety of vaginal progesterone preparations (Crinone, Cyclogest, Lutigest or Utrogestan Vaginal) for LPS in assisted reproductive technology cycles...
June 2018: Reproductive Biomedicine Online
Francis Brako, Bahijja Tolulope Raimi-Abraham, Suntharavathanan Mahalingam, Duncan Q M Craig, Mohan Edirisinghe
Recent evidence has continued to support the applicability of progesterone in preventing preterm birth, hence the development of an appropriate vaginal delivery system for this drug would be of considerable interest. Here, we describe the development of progesterone-loaded bioadhesive nanofibers using pressurized gyration for potential incorporation into a vaginal insert, with a particular view to addressing the challenges of incorporating a poorly water-soluble drug into a hydrophilic nanofiber carrier. Polyethylene oxide and carboxymethyl cellulose were chosen as polymers to develop the carrier systems, based on previous evidence of their yielding mucoadhesive nanofibers using the pressurized gyration technique...
April 5, 2018: International Journal of Pharmaceutics
Amal Yaseen Zaman, Serdar Coskun, Ahmed Abdullah Alsanie, Khalid Arab Awartani
Background: The requirement for luteal phase support (LPS) in stimulated IVF cycles is well established, however drug choice, and route of administration and duration of use are not. This report evaluates patients' preference and satisfaction by using either vaginal or intramuscular (IM) progesterone (P) supplementation for luteal phase support after in vitro fertilization and embryo transfer (IVF-ET). Methods: It is a prospective cohort study done in a reproductive and infertility unit in a tertiary care hospital from March 2013 through February 2015 for four hundred and nine patients undergoing IVF-ET...
2017: Fertility Research and Practice
Ashraf Aleyasin, Marzieh Aghahosseini, Leili Safdarian, Maryam Noorzadeh, Parvin Fallahi, Zahra Rezaeian, Sedighe Hoseinimosa
BACKGROUND: There are different methods in endometrial preparation for frozen-thawed embryo transfer (FET). OBJECTIVE: The purpose of this study was to compare the live birth rate in the artificial FET protocol (estradiol/ progesterone with GnRH-agonist) with stimulated cycle FET protocol (letrozole plus HMG). MATERIALS AND METHODS: This randomized clinical trial included 100 women (18-42 years) randomly assigned to two groups based on Bernoulli distribution...
February 2017: International Journal of Reproductive Biomedicine (Yazd, Iran)
Abootaleb Beigi, Arezoo Esmailzadeh, Reyhane Pirjani
BACKGROUND: Threatened miscarriage is a common complication in pregnancy that leads to adverse pregnancy outcomes such as preterm labor. This study aimed to compare the vaginal progesterone (Cyclogest) versus 17-alpha-hydroxyprogesterone caproate (Proluton) on preventing preterm labor in pregnant women with threatened abortion at less than 34 weeks' gestational age. MATERIALS AND METHODS: This balanced randomized, double-blind, single-center controlled clinical trial included 190 women with threatened abortion...
July 2016: International Journal of Fertility & Sterility
Afsar Sadat Tabatabaei Bafghi, Elham Bahrami, Leila Sekhavat
BACKGROUND: Preterm birth is a worldwide health concern due to its various negative consequences. Therefore, the prevention of preterm birth is a top priority for healthcare systems in all countries. OBJECTIVE: To compare the effectiveness of vaginal versus intramuscular progesterone in the prevention of preterm delivery. METHODS: This randomized clinical trial was conducted at Shahid Sadoughi Hospital in Yazd, Iran, from November 21, 2012 to January 20, 2015...
October 2015: Electronic Physician
Donya Khosravi, Robabeh Taheripanah, Anahita Taheripanah, Vahid Tarighat Monfared, Seyed-Mostafa Hosseini-Zijoud
BACKGROUND: The aim of this study, we have compared the advantages of oral dydrogestrone with vaginal progesterone (cyclogest) for luteal support in intrauterine insemination (IUI) cycles. Progesterone supplementation is the first line treatment when luteal phase deficiency (LPD) can reasonably be assumed. OBJECTIVE: This study was conduct to compare the effect of oral dydrogestrone with vaginal Cyclogest on luteal phase support in the IUI cycles. MATERIALS AND METHODS: This prospective, randomized, double blind study was performed in a local infertility center from May 2013 to May 2014...
July 2015: Iranian Journal of Reproductive Medicine
Elham Azimi Nekoo, Maryam Chamani, Ensieh Shahrokh Tehrani, Batool Hossein Rashidi, Fatemeh Davari Tanha, Vahid Kalantari
OBJECTIVE: To investigate the reproductive outcome of artificial endometrial preparation with exogenous steroids for frozen-thawed embryo transfer with and without pre-treatment with depot gonadotropin releasing hormone agonist (GnRH-a) in women with regular menses. MATERIALS AND METHODS: This is a prospective randomized clinical trial conducted in two ART centers on 176 women undergoing frozen-thawed embryo transfer. All patients received oral estradiol valerate 4 mg daily from day 2 to day 5 and 6 mg per day from day 6 to the day of the pregnancy test...
March 2015: Journal of Family & Reproductive Health
Fatemeh Foroozanfard, Hamidreza Saberi, Seyed Alireza Moraveji, Fatemeh Bazarganipour
BACKGROUND: To assess the efficacy of luteal phase support (LPS) using intravaginal progesterone (P) on pregnancy rate in Iranian women with polycystic ovarian syndrome (PCOS) who used a combination for ovulation induction consisting of letrozole or clomi- phene citrate (CC) and human menopausal gonadotropin (HMG). MATERIALS AND METHODS: This was a randomized clinical trial undertaken in a fertility clinic in Kashan, Isfahan Province, Iran. A total of 198 patients completed treatment and follow up...
October 2014: International Journal of Fertility & Sterility
Fakhrolmolouk Yassaee, Reza Shekarriz-Foumani, Shabnam Afsari, Masoumeh Fallahian
BACKGROUND: Threatened abortion is a common complication of pregnancy. In order to prevent miscarriage in the cases with threatened abortion, this study was conducted to determine whether progesterone suppository is effective in allowing pregnancy to proceed beyond week 20 in women with threatened abortion. METHODS: This single-blind clinical trial study was done on 60 pregnant women with threatened abortion. Pregnant women, who had vaginal bleeding until 20 weeks of their pregnancy, were assessed for inclusion...
July 2014: Journal of Reproduction & Infertility
Richard Russell, Charles Kingsland, Zarko Alfirevic, Rafet Gazvani
Luteal support is considered as an essential component of IVF treatment following ovarian stimulation and embryo transfer. Several studies have consistently demonstrated a benefit of luteal support compared with no treatment and whilst a number of preparations are available, no product has been demonstrated as superior. There is an emerging body of evidence which suggests that extension of luteal support beyond biochemical pregnancy does not confer a benefit in terms of successful pregnancy outcome. We performed two surveys separated by 5 years of practice evolution, with the latter reporting on the use of luteal support in all IVF clinics in the UK...
March 2015: Human Fertility: Journal of the British Fertility Society
Bibi Shahnaz Aali, Sakineh Ebrahimipour, Siavash Medhdizadeh
BACKGROUND: Controlled ovarian stimulation combined with intra uterine insemination (IUI) is a convenient treatment of infertility with a success rate of 11%. The clinical observation and pattern of progesterone secretion in this method is suggestive of luteal phase defect and postulated as an implicating factor of treatment failure. OBJECTIVE: To investigate the efficacy of luteal phase support with intravaginal cyclogest in women undergoing controlled ovarian stimulation combined with intrauterine insemination...
April 2013: Iranian Journal of Reproductive Medicine
Saghar Salehpour, Maryam Tamimi, Nasrin Saharkhiz
BACKGROUND: Luteal phase support is mandatory in assisted reproductive technologies (ART) for optimizing outcome, so the luteal phase is supported with either progesterone, addition of estradiol to progesterone, hCG or gonadotropin releasing hormone (GnRH) agonists. Supplementation of luteal phase with progesterone is prescribed for women undergoing routine IVF treatment. OBJECTIVE: To compare oral dydrogestrone with vaginal progesterone for luteal-phase support in IVF...
November 2013: Iranian Journal of Reproductive Medicine
Malek-Mansour Aghsa, Haleh Rahmanpour, Maryam Bagheri, Fatemeh Davari-Tanha, Reza Nasr
PURPOSE: This study compares the efficacy, side effects and patient convenience of vaginal and rectal routes of administration of progesterone suppositories (Cyclogest) when used for luteal phase support during in vitro fertilization cycles, through the use of antagonist protocols. METHODS: 147 patients who underwent intra-cytoplasmic sperm injection cycle were randomized on the day of the embryo transfer (ET) by a computer-generated randomization program to receive 400 mg of Cyclogest either vaginally or rectally twice daily for up to 8 weeks...
October 2012: Archives of Gynecology and Obstetrics
Ernest Hung Yu Ng, Carina Chi Wai Chan, Oi Shan Tang, Pak Chung Ho
OBJECTIVE: This study compared side effects and patient convenience of vaginal progesterone suppositories (Cyclogest) and vaginal progesterone tablets (Endometrin) used for luteal phase support in in vitro fertilization/embryo transfer (IVF/ET) cycles using pituitary downregulation. STUDY DESIGN: One hundred and thirty-two infertile patients were randomized on the day of ET by a computer-generated randomization list in sealed envelopes to receive either Cyclogest 400mg or Endometrin 100mg twice daily for 14 days...
April 2007: European Journal of Obstetrics, Gynecology, and Reproductive Biology
P Y S Tay, E A Lenton
This is a prospeve randomised study designed to clarify the impact of various luteal support regimes (HCG and progesterone) on progesterone profiles and pregnancy outcomes. This study involved subjects undergone down regulated. stimulated IVF cycles using various types of luteal support, namely: Cyclogest (n=35). Crinone gel (n=36), various doses of Utrogestan (n=55) and HCG (n=35). Various doses of Utrogestan (administered vaginally), Crinone gel (progesterone administered vaginally) and Cyclogest (progesterone administered rectally) supplementation induced similar end plasma progesterone concentrations ranging from 26 to 32 mmnl/l...
June 2005: Medical Journal of Malaysia
P Y Tay, E A Lenton
A prospective randomised study was done to assess the effect of supplemental oestradiol in addition to progesterone on the luteal steroid profiles and pregnancy outcome in stimulated cycles with and without pituitary down regulation. Women undergoing stimulated cycle IVF with GnRH-a and FSH (Group A, n = 63) or stimulated intrauterine insemination using CC and FSH (Group B, n = 55) were studied. These subjects were randomly allocated to receive either 400 mg daily of vaginally administrated Cyclogest (progesterone) alone or in combination with 2 mg daily of oral Oestradiol Valerate (E2V) during the luteal phase...
June 2003: Medical Journal of Malaysia
Ernest H Y Ng, Benyu Miao, Wai Cheung, Pak-Chung Ho
OBJECTIVE: To compare side effects and patient inconvenience of two vaginal progesterone (P) formulations for luteal support in in vitro fertilisation cycles. STUDY DESIGN: Sixty infertile patients at risk of developing ovarian hyperstimulation syndrome were randomised to receive either Cyclogest vaginal suppositories 400mg twice daily or Crinone 8% vaginal gel once daily for 14 days as the luteal support. On Day 6 and Day 16 after embryo transfer, they rated side effects and patient inconvenience into four grades: none, mild, moderate and severe by completing a questionnaire...
November 10, 2003: European Journal of Obstetrics, Gynecology, and Reproductive Biology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"